LaserSight LaserScan LSX For LASIK Myopia Correction To Ship By Year-End
This article was originally published in The Gray Sheet
Executive Summary
LaserSight LaserScan LSX systems equipped for laser in-situ keratomileusis (LASIK) treatment of myopia with or without astigmatism will ship by year-end following FDA approval of the expanded indication.
You may also be interested in...
Refractec ViewPoint Comparative Claims Questioned During Panel Review
Reservations raised by FDA's Ophthalmic Devices Panel regarding claims by Refractec about the less invasive nature of its ViewPoint conductive keratoplasty (CK) system compared with LASIK highlight the challenges the firm may face in differentiating its product from other refractive devices for treating hyperopia
Refractec ViewPoint Comparative Claims Questioned During Panel Review
Reservations raised by FDA's Ophthalmic Devices Panel regarding claims by Refractec about the less invasive nature of its ViewPoint conductive keratoplasty (CK) system compared with LASIK highlight the challenges the firm may face in differentiating its product from other refractive devices for treating hyperopia
LaserSight Excimer Laser Sales On Hold Pending Visx License Negotiations
LaserSight says it will delay marketing of the LaserScan LSX ophthalmic excimer laser system in the U.S. while it negotiates a license agreement with competitor Visx.